| Q57151364 | A Single-Cell Transcriptional Atlas of the Developing Murine Cerebellum |
| Q57804817 | A biobank of patient-derived pediatric brain tumor models |
| Q38831823 | A cell-based model system links chromothripsis with hyperploidy |
| Q45957975 | AT-03ATYPICAL TERATOID/RHABDOID TUMOUR IS A GENETICALLY HOMOGENEOUS BUT EPIGENETICALLY HETEROGENEOUS DISEASE THAT IS DEFINED BY SUBGROUP SPECIFIC SUPER-ENHANCERS. |
| Q39023964 | Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas |
| Q36631618 | Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. |
| Q57289007 | Abstract 3089: (Epi)genetic profiling enables molecular re-classification of CNS-primitive neuroectodermal tumors |
| Q57289083 | Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups |
| Q61917646 | Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells |
| Q57199717 | Abstracts |
| Q37517791 | Active medulloblastoma enhancers reveal subgroup-specific cellular origins |
| Q55463035 | Adult medulloblastoma comprises three major molecular variants. |
| Q91752198 | Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic |
| Q35774418 | An animal model of MYC-driven medulloblastoma |
| Q39910333 | An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma |
| Q48471843 | Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy |
| Q48872957 | Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes |
| Q57141596 | Author Correction: The landscape of genomic alterations across childhood cancers |
| Q55462417 | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. |
| Q42503619 | Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. |
| Q94938041 | Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen |
| Q61829341 | CELL BIOLOGY AND SIGNALING |
| Q41760694 | CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma |
| Q55463800 | Calculating a cure for cancer: managing medulloblastoma MATH1-ematically. |
| Q48210831 | Cancer: Keeping it real to kill glioblastoma |
| Q48381540 | Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development |
| Q37719291 | Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. |
| Q35784926 | Clonal selection drives genetic divergence of metastatic medulloblastoma |
| Q90814322 | Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation |
| Q92178889 | Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials |
| Q34776833 | Coverage bias and sensitivity of variant calling for four whole-genome sequencing technologies |
| Q34031780 | Cross-species genomics matches driver mutations and cell compartments to model ependymoma |
| Q36585123 | Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies |
| Q37627692 | Cytogenetic prognostication within medulloblastoma subgroups |
| Q96585175 | DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma |
| Q28282708 | DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies |
| Q52655770 | DNA methylation-based classification of central nervous system tumours. |
| Q50063187 | DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma |
| Q38993103 | Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing |
| Q104062835 | Deconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond |
| Q35896018 | Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. |
| Q50051453 | Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. |
| Q59133452 | Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors |
| Q34132926 | Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma |
| Q112722613 | Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth |
| Q24621907 | Dissecting the genomic complexity underlying medulloblastoma |
| Q35989886 | Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. |
| Q48915503 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system |
| Q37073617 | Divergent clonal selection dominates medulloblastoma at recurrence |
| Q38194990 | Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent |
| Q58034315 | EPENDYMOMA |
| Q45832596 | EPIG-04THE CHROMATIN LANDSCAPE OF MEDULLOBLASTOMA. |
| Q33917715 | Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity |
| Q34362028 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma |
| Q34480576 | Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. |
| Q34240198 | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy |
| Q57082606 | Erratum: Corrigendum: Signatures of mutational processes in human cancer |
| Q37971394 | FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. |
| Q55624498 | FORETINIB IS EFFECTIVE THERAPY FOR METASTATIC SONIC HEDGEHOG MEDULLOBLASTOMA. |
| Q34215755 | FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma |
| Q38940977 | Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. |
| Q36296016 | Functional genomics identifies drivers of medulloblastoma dissemination |
| Q98611283 | Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation |
| Q45956799 | GE-07DNA METHYLATION IN MEDULLOBLASTOMA AND MOLECULAR DIAGNOSTICS OF BRAIN TUMORS. |
| Q57289055 | GE-21 * DRASTIC GENOMIC DIVERGENCE OF RECURRENT MEDULLOBLASTOMA INVALIDATES TARGETED THERAPIES DISCOVERED AT DIAGNOSIS |
| Q45824431 | GE-23ENHANCER HIJACKING ACTIVATES GFI1 FAMILY ONCOGENES IN MEDULLOBLASTOMA. |
| Q39752244 | Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. |
| Q27852966 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition |
| Q34248736 | Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations |
| Q38667981 | Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. |
| Q43671177 | Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts |
| Q37665521 | Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years |
| Q91971805 | Germline Elongator mutations in Sonic Hedgehog medulloblastoma |
| Q90691513 | Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma |
| Q36951069 | Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. |
| Q48227278 | HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth |
| Q33274578 | High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis |
| Q37503144 | Hypermutation of the inactive X chromosome is a frequent event in cancer |
| Q55026482 | ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. |
| Q24320317 | Identification of a WD40 repeat-containing isoform of PHIP as a novel regulator of beta-cell growth and survival |
| Q33633473 | Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma |
| Q41264935 | Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers |
| Q38120467 | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. |
| Q42085653 | LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR) |
| Q92659630 | Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma |
| Q60907391 | Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma |
| Q45956091 | MB-08MOLECULAR (RE-)CLASSIFICATION OF CNS-PRIMITIVE NEUROECTODERMAL TUMORS. |
| Q46354278 | MB-17FUNCTIONAL CHARACTERIZATION OF RECURRENTLY MUTATED NEURONAL TRANSCRIPTION FACTORS IN MEDULLOBLASTOMA. |
| Q46354298 | MB-18DYSFUNCTION OF THE CHROMATIN REMODELER Chd7 CAUSES ABNORMAL CEREBELLAR DEVELOPMENT AND ACCELERATES MEDULLOBLASTOMA FORMATION. |
| Q45957864 | MB-25REGULATION OF MEDULLOBLASTOMA FORMATION BY Gfi1 AND Gfi1b. |
| Q46354746 | MB-44SUBGROUP-SPECIFIC QUANTITATIVE PROTEOMIC ANALYSIS OF MEDULLOBLASTOMA. |
| Q45742611 | MB-46PROGNOSTIC RELEVANCE OF EPIGENETIC/BIOLOGICAL SUBGROUPS AND MYCC/MYCN GENE AMPLIFICATION IN A HOMOGENOUSLY TREATED METASTATIC MEDULLOBLASTOMA HIT2000 COHORT AGED 4-21 YEARS. |
| Q94067925 | MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP |
| Q94067789 | MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY |
| Q64972831 | MBCL-41. TREATMENT FAILURE PATTERNS ACROSS MEDULLOBLASTOMA SUBGROUPS WITHIN A PROSPECTIVE PHASE II CLINICAL TRIAL OF RISK-ADAPTED, VOLUME-REDUCED RADIATION THERAPY AND DOSE-INTENSE CHEMOTHERAPY WITH STEM CELL SUPPORT. |
| Q94065878 | MBCL-42. SECOND GENERATION MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA: TOWARDS A WORKING CONSENSUS OF GROUP 3/4 SUBTYPES |
| Q94065636 | MBCL-44. THE MOLECULAR AND CLINICAL LANDSCAPE OF INFANT MEDULLOBLASTOMA (iMB): RESULTS AND MOLECULAR ANALYSIS FROM A PROSPECTIVE, MULTICENTER PHASE II TRIAL (SJYC07) |
| Q94067735 | MBRS-07. BCOR LOSS IMPACTS SHH MEDULLOBLASTOMA FORMATION VIA TRANSCRIPTIONAL UP-REGULATION OF |
| Q64983697 | MBRS-19. BIOCHEMICAL AND ONCOGENIC CHARACTERIZATION OF HOTSPOT KBTBD4 MUTATIONS IN MEDULLOBLASTOMA. |
| Q94068107 | MBRS-28. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF MEDULLOBLASTOMA |
| Q64926246 | MBRS-34. MOLECULAR CHARACTERIZATION OF RECURRENT MEDULLOBLASTOMA REVEALS AN UNEXPECTEDLY HIGH INCIDENCE OF SECONDARY MALIGNANCY. |
| Q94331854 | MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION |
| Q54855151 | MEDU-24. INSTRUMENTAL ROLE OF THE PHOTORECEPTOR PROGRAM IN GROUP 3 MEDULLOBLASTOMA THROUGH THE TRANSCRIPTION FACTOR NRL. |
| Q58177980 | MEDULLOBLASTOMA |
| Q56880484 | MEDULLOBLASTOMA |
| Q64947029 | MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. |
| Q46032472 | MOLECULAR (RE-)CLASSIFICATION OF CNS-PRIMITIVE NEUROECTODERMAL TUMORS. |
| Q91596369 | Medulloblastoma |
| Q42739353 | Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. |
| Q36920479 | Medulloblastoma comprises four distinct molecular variants |
| Q30040534 | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations |
| Q91679780 | Medulloblastoma genomics in the modern molecular era |
| Q35099027 | Medulloblastoma subgroups remain stable across primary and metastatic compartments |
| Q37317515 | Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress |
| Q91826570 | Medulloblastomics revisited: biological and clinical insights from thousands of patients |
| Q37469904 | Medulloblastomics: the end of the beginning |
| Q53201641 | MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. |
| Q27350129 | MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma |
| Q45826769 | Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma |
| Q35101347 | Molecular subgroups of medulloblastoma |
| Q34167499 | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas |
| Q24615271 | Molecular subgroups of medulloblastoma: the current consensus |
| Q37896219 | Mouse models of medulloblastoma |
| Q39334547 | Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor |
| Q28237604 | Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma |
| Q33584640 | MyoD is a tumor suppressor gene in medulloblastoma |
| Q57954536 | NEURO/MEDICAL ONCOLOGY |
| Q52658142 | NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. |
| Q34515911 | New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs |
| Q34576839 | Nexilin, a cardiomyopathy-associated F-actin binding protein, binds and regulates IRS1 signaling in skeletal muscle cells |
| Q38525123 | Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies |
| Q37630205 | Normal and oncogenic roles for microRNAs in the developing brain |
| Q39205931 | Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation |
| Q41701616 | Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells |
| Q56898447 | OMICS AND PROGNSTIC MARKERS |
| Q42423388 | OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas |
| Q36641703 | Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation |
| Q104753822 | Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03) |
| Q39539408 | PCDH10 is a candidate tumour suppressor gene in medulloblastoma. |
| Q46357280 | PCM-15SOMATIC CRISPR/Cas9-MEDIATED TUMOR SUPPRESSOR DISRUPTION ENABLES VERSATILE BRAIN TUMOR MODELING. |
| Q56999046 | PEDIATRICS LABORATORY RESEARCH |
| Q45957447 | PM-09ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS. |
| Q94354022 | PM-09REGULATION OF MEDULLOBLASTOMA FORMATION BY Gfi1 AND Gfi1B |
| Q57954516 | PROGNOSTIC SIGNIFICANCE OF CLINICAL, HISTOPATHOLOGICAL, AND MOLECULAR CHARACTERISTICS OF MEDULLOBLASTOMAS IN THE PROSPECTIVE HIT2000 MULTICENTER CLINICAL TRIAL COHORT |
| Q45834943 | PTPS-11ATYPICAL TERATOID/RHABDOID TUMOUR IS AN EPIGENETICALLY HETEROGENEOUS DISEASE CHARACTERIZED BY SUBGROUP SPECIFIC SUPER-ENHANCERS. |
| Q34545220 | Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. |
| Q112645015 | Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma |
| Q96232268 | Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource |
| Q98191465 | Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma |
| Q35960250 | Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct |
| Q34982536 | Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children |
| Q91488034 | Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221) |
| Q40461175 | Pleiotropic role for MYCN in medulloblastoma. |
| Q33764662 | Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort |
| Q37004219 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis |
| Q55479624 | Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. |
| Q35630706 | Proteomic profiling of high risk medulloblastoma reveals functional biology |
| Q57158811 | Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups |
| Q35635358 | Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma |
| Q35837393 | Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples |
| Q37312706 | Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas |
| Q37636027 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis |
| Q34354839 | Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma |
| Q24339074 | Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas |
| Q92154185 | Resolving medulloblastoma cellular architecture by single-cell genomics |
| Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
| Q91699914 | Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials |
| Q88737429 | Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial |
| Q43153279 | Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays |
| Q30156001 | Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma |
| Q46225692 | STRUCTURAL VARIANTS SHUFFLE CHROMATIN TO ACTIVATE GFI1 FAMILY ONCOGENES IN MEDULLOBLASTOMA. |
| Q92484009 | SWI/SNF complex heterogeneity relates with polyphenotypic differentiation, prognosis and immune response in rhabdoid tumors |
| Q91933328 | Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes |
| Q29547191 | Signatures of mutational processes in human cancer |
| Q38340521 | Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma |
| Q35742331 | Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling |
| Q39521830 | Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. |
| Q41969132 | Spatial heterogeneity in medulloblastoma |
| Q54969362 | Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. |
| Q28260516 | Subgroup-specific alternative splicing in medulloblastoma |
| Q36929844 | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma |
| Q28271811 | Subgroup-specific structural variation across 1,000 medulloblastoma genomes |
| Q46359308 | TB-17A COMPREHENSIVE PAN-CANCER ANALYSIS OF CHILDHOOD MALIGNANCIES. |
| Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
| Q45836126 | TMOD-01BCOR IS A NOVEL TUMOR SUPPRESSOR GENE IN SHH-DRIVEN MEDULLOBLASTOMA. |
| Q42689215 | Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. |
| Q36032753 | Targeting the enhancer of zeste homologue 2 in medulloblastoma. |
| Q92352124 | TelomereHunter - in silico estimation of telomere content and composition from cancer genomes |
| Q38321654 | The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis |
| Q24301908 | The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma |
| Q48508947 | The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors |
| Q36490004 | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants |
| Q38008153 | The clinical implications of medulloblastoma subgroups |
| Q28291406 | The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation |
| Q37987505 | The epigenetics of brain tumors. |
| Q37439475 | The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective. |
| Q28301196 | The genetic landscape of the childhood cancer medulloblastoma |
| Q37738138 | The genetics of pediatric brain tumors |
| Q50421569 | The landscape of genomic alterations across childhood cancers. |
| Q24629817 | The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors |
| Q38083796 | The role of chromatin remodeling in medulloblastoma. |
| Q46567834 | The whole-genome landscape of medulloblastoma subtypes |
| Q47906350 | Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling |
| Q38123270 | Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics |
| Q39174290 | Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters |
| Q42558518 | Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization |
| Q64939961 | Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. |
| Q56968690 | UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs |
| Q24294672 | Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics |
| Q34979270 | WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma |
| Q98283974 | WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup? |
| Q28507494 | YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation |
| Q92163648 | scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy |